GeneDx Names Everett Cunningham as New CEO
The Stamford-headquartered genetic testing company is replacing longtime chief executive Katherine Stueland, who is departing after more than five years in the role.
Updated on Nov. 18, 2026 in Biotech

Live Poll
Do you trust large Connecticut companies to keep their promises to the state?
GeneDx named Everett Cunningham as its chief executive, succeeding Katherine Stueland, who stepped down after more than five years leading the company. Cunningham will take over by December 15 and join the GeneDx board.
Why it matters
The leadership change comes as GeneDx, which grew out of Sema4 and is headquartered in Stamford, works to stabilize operations following a 2022 restructuring that eliminated about 700 jobs. Cunningham's background includes prior leadership roles at Quanterix, Illumina and Exact Sciences.
GeneDx reported third-quarter revenue of $123.1 million, up 5% from a year earlier, with volume growth of 25% for its main genetic test types. The company reaffirmed a full-year revenue forecast of $475 million to $490 million, while the reasons behind the CEO transition were not addressed.
The players
GeneDx
GeneDx is a genetic testing company headquartered in Stamford, Connecticut, that was acquired by Sema4 in 2022 and operates a main laboratory in Gaithersburg, Maryland.
Everett Cunningham
Everett Cunningham is a diagnostics executive who previously held senior commercial roles at Illumina and Exact Sciences and led Quanterix.
Katherine Stueland
Katherine Stueland led GeneDx for more than five years before stepping down as chief executive.
The details
Katherine Stueland stepped down as chief executive and left the board when Everett Cunningham took over; she remains an adviser through January 31. Cunningham previously led diagnostics company Quanterix from January to November and served as chief commercial officer at Illumina and Exact Sciences. GeneDx President Mark Gardner will report to Cunningham.
Timeline
2021: Sema4, GeneDx's former parent, went public.
2022: Sema4 acquired GeneDx for $623 million and closed its Stamford and Branford labs.
May 2025: Hartford Business Journal reported GeneDx was seeking to sublet space.
First quarter of 2026: GeneDx repaid the remaining $4.5 million of its Connecticut DECD loan.
December 15, 2026: Cunningham is set to succeed Stueland as CEO.
The Tech Race
The CEO change follows Sema4's 2022 purchase of GeneDx for $623 million and the closure of its Stamford and Branford labs, which eliminated about 700 jobs. Connecticut's $15.5 million loan to Sema4 for its Stamford headquarters has since been repaid in full.
For patients and healthcare providers who rely on GeneDx genetic tests, the leadership change does not alter currently offered services in the information provided. The company's full-year revenue forecast of $475 million to $490 million was reaffirmed, which signals no immediate change in its testing business.
The takeaway
Leadership transitions at healthcare technology companies often follow periods of restructuring, and GeneDx's appointment of a veteran diagnostics commercial executive signals a focus on growth and market execution. Readers tracking the company should watch whether its reaffirmed revenue forecast holds through the transition.
What happens next
Cunningham is scheduled to succeed Stueland as chief executive by December 15, 2026, and to join the GeneDx board at that time.
Further reading
For more on the industry, see Biotech coverage of genetic testing companies and their leadership changes.
Source note: This article includes information reported by Hartford Business Journal.
Live Poll
Do you trust large Connecticut companies to keep their promises to the state?






